OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director exercised or converted 6,142 ALKS derivative securities | OQRO

Home
Insider trades
Alkermes plc
Director exercised or converted 6,142 ALKS derivative securities

Insider trades

Insider trade

Director exercised or converted 6,142 ALKS derivative securities

Traded May 21, 2026 · Filed May 23, 2026

ALKAlkermes plcALKS

6,142
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 21, 2026
Reporting period: Not applicable
Filed with the SEC: May 23, 2026

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001520262-26-000090

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

May 23, 2026, 12:03 AM UTC

Added to OQRO

Oct 6, 2026, 9:54 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Alkermes plc.

Issuer CIK

1520262

Ticker

ALKS

Reporting person

Brian P Mckeon

Relationship

Director

Security

Restricted Stock Unit Award

Table

Derivative (Table II)

Transaction date

May 21, 2026

Transaction code

Shares / units

6,142

Acquired / disposed

Disposed (D)

Shares owned after

Ownership form

Direct

Amendment

Footnotes from the filing

Each restricted stock unit represents a contingent right to receive one ordinary share.
This award is fully vested in accordance with its terms.

Around the same time

Christopher I Wright (Director) sold ~$90K of Alkermes plc

Scheduled in advanceFiled 4mo ago

David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold ~$88K of Alkermes plc

Scheduled in advanceFiled 4mo ago

Craig C. HopkinsonEVP R&D, Chief Medical Officer

Filed 4mo ago

5,000Shares · @ $19.34

Traded Jun 1 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record